PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

This study is using a blood-based tool called ctDNA (circulating tumor DNA — tiny fragments of cancer DNA found in the blood) to guide personalized treatment decisions for people with early-stage lung cancer before surgery. The goal is to tailor how much immunotherapy and chemotherapy each person receives based on how their cancer is responding. **You may be eligible if...** - You have been diagnosed with non-small cell lung cancer (NSCLC) at stage IIA to IIIB - Your cancer has been assessed as surgically removable by a medical team - Your cancer does not carry EGFR or ALK mutations (unless it is squamous cell type) - You are in good overall health (ECOG 0 to 1) - You have not yet received any treatment for this lung cancer **You may NOT be eligible if...** - You have an active autoimmune disease requiring treatment - You are taking high-dose steroids - You have severe lung disease (Grade 3-4 interstitial lung disease) - You have previously received immunotherapy (PD-1, PD-L1, or CTLA-4 blockers) - You have active hepatitis B or C, or HIV - You are pregnant Talk to your doctor to see if this trial is right for you.